J Korean Soc Pediatr Nephrol.  2002 Apr;6(1):56-60.

Efficacy of 23-valent Pneumococcal Polysaccharide Vaccine in Steroid Responsive Nephrotic Syndrome

• Hahn HW
• Ha IS
• Cheong HI
• Lee HJ
• Choi Y

Abstract

PURPOSE: Streptococcus pneumoniae is a major pathogen in both adults and children, causing significant morbidity and mortality. In patients with nephrotic syndrome, Streptococcus pneumoniae is a major cause of spontaneous peritonitis, and the increasing incidence of penicillin-resistance strain facilitates the development of effective vaccine. The limitation of current pneumococcal polysaccharide vaccine prompted development of polysaccharide-protein conjugate vaccine.
METHODS
We reviewed the medical record of total 225 steroid responsive nephrotic patients to ascertain the effectiveness of 23-valent pneumococcal polysaccharide vaccine.
RESULTS
Twenty-eight patients have developed peritonitis during the courses, and 7 of those have recurrent peritonitis. Fifty-five patients were vaccinated and followed-up for 1-108 months (mean 38.5 months), and during the follow-up period, pneumococcus related peritonitis was not detected. Vaccine-related relapse of nephrotic syndrome was absent.
CONCLUSION
In spite of the non-consensus about the efficacy of PPV23, clinically it benefits, and until the clinical trial of PCV7 is completed, PPV23 will be recommended.

Keyword

Nephrotic syndrome; Peritonitis; S. pneumoniae; Pneumococcal vaccine

MeSH Terms

Adult
Child
Follow-Up Studies
Humans
Incidence
Medical Records
Mortality
Nephrotic Syndrome*
Peritonitis
Pneumococcal Vaccines*
Recurrence
Streptococcus pneumoniae
Pneumococcal Vaccines